Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma
Nivo/ipi produced favorable outcomes in patients with pRCC supporting its use as 1 L therapy. Responses in patients with chRCC were noted exclusively with SF. Despite achieving an ORR of 27.8% with nivo/ipi, patients with uRCC had short PFS and inferior OS.
Authors
- Devaki Shilpa Surasi (ORCID: https://orcid.org/0000-0003-3174-1138)
- Omar Alhalabi (ORCID: https://orcid.org/0000-0002-9658-2206)
- Eric Jonasch (ORCID: https://orcid.org/0000-0003-0943-2806)
- Matthew T. Campbell (ORCID: https://orcid.org/0000-0003-1915-4491)
- Elshad Hasanov (ORCID: https://orcid.org/0000-0002-7195-0842)
- Andrew Johns (ORCID: https://orcid.org/0000-0001-9821-8662)
- Amishi Y. Shah (ORCID: https://orcid.org/0000-0002-9007-0621)
- Jaanki Khandelwal
- Kanishka Sircar (ORCID: https://orcid.org/0000-0001-9515-697X)
- Sangeeta Goswami (ORCID: https://orcid.org/0000-0001-9201-4503)
- Nizar M. Tannir (ORCID: https://orcid.org/0000-0001-5559-8060)
- Khaled M. Elsayes (ORCID: https://orcid.org/0000-0003-0184-0717)
- Yiyun Lin (ORCID: https://orcid.org/0000-0002-9277-3048)
- Nathaniel R. Wilson (ORCID: https://orcid.org/0000-0002-9123-1781)
- Pavlos Msaouel (ORCID: https://orcid.org/0000-0001-6505-8308)
- Tharakeswara Bathala (ORCID: https://orcid.org/0000-0001-8342-4519)
- Kiran L Malikayil
- Helen Ajufo
- Pheroze Tamboli
- Mohammad Jad Moussa (ORCID: https://orcid.org/0009-0000-7960-8614)
- Priya Rao
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Washington University in St. Louis (US)
- University of Michigan (US)
- Baylor University Medical Center (US)
- The Ohio State University Wexner Medical Center (US)
- The Ohio State University (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/jitc-2024-010958
- Citations
- 8
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 12.15
Funders
- Gateway for Cancer Research
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Exelixis
- Arrowhead Pharmaceuticals
- Pelotonia
- Mirati Therapeutics
- Calithera Biosciences
- Cardinal Health
- Silverback Therapeutics
- Seagen
- Eisai
- Astellas Pharma
- Ono Pharmaceutical
- Ipsen
- Aptitude Health
- Genentech
- EMD Serono
- University of Texas MD Anderson Cancer Center